Table 2: Radiation-absorbed doses to organs from 188Re-6D2 (mSv/MBq).

CohortLiverSpleenKidneysBone marrowUrine bladder wallWhole body

Phase 1a
 Cohort 10.88 ± 0.130.86 ± 0.091.35 ± 0.050.09 ± 0.010.88 ± 0.230.16 ± 0.01
 Cohort 20.89 ± 0.200.67 ± 0.051.11 ± 0.220.11 ± 0.021.01 ± 0.120.15 ± 0.03
 Cohort 30.90 ± 0.080.73 ± 0.141.59 ± 0.010.11 ± 0.00.86 ± 0.140.13 ± 0.02
 Cohort 41.04 ± 0.300.67 ± 0.301.29 ± 0.120.14 ± 0.031.02 ± 0.080.16 ± 0.04
Phase 1b
 Cohort 10.92 ± 0.20 0.93± 0.321.99 ± 0.17 0.11± 0.01 0.61 ± —* 0.14 ± 0.01
 Cohort 2 0.77 ± 0.25 1.02 ± 0.35 1.75 ± 0.25 0.10 ± 0.01 0.95 ± 0.47 0.15 ± 0.03
Tositumomab 0.821.141.960.650.640.24
Ibritumomab tiuxetan4.89.40.11.30.90.5

*Only one patient had sufficient data for calculation of urine bladder wall dose.